CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CG Oncology, Inc. Chief Commercial Officer Isabel Kalofonos received 92,000 employee stock options on October 15, 2026, with an exercise price of $61.86 per share and an expiration date of October 14, 2036. The options have a four-year vesting period beginning October 13, 2026, subject to continuous service through each vesting date.
Leonard E. Post, a director of CG Oncology, Inc., exercised options covering 1,000 common shares at an exercise price of $0.60 per share on October 15, 2026. On the same date, he sold two blocks of 500 shares at weighted average prices of $61.65 and $62.48 per share. The sales were made under a Rule 10b5-1 trading plan adopted March 5, 2026. His reported post-exercise director stock option position was 102,077 shares.
CG Oncology, Inc. (CGON) lists director Leonard Post’s planned sale of 3,000 common shares, with an aggregate market value of $185,520 and a listed sale date of October 15, 2026. The shares are to be received through stock-option exercises over the next three months; the notice says acquisition and payment dates were and will be the exercise/sale dates. It lists 88,640,375 shares outstanding. Morgan Stanley Smith Barney LLC is listed as broker, and NASDAQ is listed as the market.
Two prior Rule 10b5-1 sales are reported: 1,000 shares on September 15, 2026, for $72,982.80, and 1,000 shares on August 14, 2026, for $74,540.00.
CG Oncology, Inc. (CGON) filed a notice under Rule 144 for planned sales of common stock by officer Ambaw Bellete. The filing lists an intended sale of 30,787 shares of common stock in connection with a stock option exercise, with Morgan Stanley Smith Barney LLC Executive Financial Services as broker and NASDAQ as the trading market.
The notice also reports multiple prior sales of CG Oncology common stock by Ambaw Bellete during the preceding three months, each with specified dates, share amounts, and dollar proceeds.
CG Oncology, Inc. (CGON) received a Rule 144 notice from officer Ambaw Bellete covering a proposed sale of 6,532 shares of common stock through Morgan Stanley Smith Barney, with a reported aggregate market value of $499,698.00, around September 17, 2026. The notice reports 88,640,375 shares of common stock outstanding.
Bellete also reports multiple prior sales of CG Oncology common stock in the past three months under Rule 144, including 100,000 shares sold on August 19, 2026 for $7,954,105.00 and several other transactions ranging from a few thousand to 50,000 shares each.
CG Oncology, Inc. (CGON) director Leonard E. Post reported an option exercise-and-sale sequence on September 15, 2026. He exercised options to acquire 1,000 shares of common stock at $0.60 per share and sold 1,000 shares of common stock at a weighted average price of $72.98 under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following the option exercise, he held 103,077 option-based rights directly.
CG Oncology, Inc. (CGON) received a notice under Rule 144 that officer Ambaw Bellete plans to sell 826 shares of common stock on September 11, 2026, following a stock option exercise for cash. The shares are to be sold through Morgan Stanley Smith Barney LLC on Nasdaq, and the notice also lists Bellete’s prior common stock sales over the preceding three months.
CG Oncology, Inc. (CGON) has a notice under Rule 144 from officer Ambaw Bellete covering the proposed sale of 29,630 shares of common stock, expected to be sold on September 2, 2026 following a stock option exercise, through Morgan Stanley Smith Barney LLC.
The notice lists an aggregate market value for these planned sales of $2,299,448.00, and states that CG Oncology had 88,640,375 shares of common stock outstanding. It also details multiple prior open-market sales by Ambaw Bellete over the past three months, including several blocks of 50,000–100,000 shares.
CG Oncology, Inc. (CGON) received a notice under Rule 144 from officer Ambaw Bellete covering a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $3,775,250.00 and 88,640,375 shares outstanding as of 08/31/2026.
The shares are to be sold on or after 08/31/2026 in connection with a stock option exercise for cash. The notice also lists multiple prior sales of CG Oncology common stock by Ambaw Bellete during the past three months, including several transactions of tens of thousands of shares.